Momenta Pharmaceuticals Inc. and partner Sandoz Inc. were the first to launch a generic version of Sanofi's blockbuster blood thinner Lovenox (enoxaparin) in July 2010. For the past six years, they have been engaged in a battle with Amphastar Pharmaceuticals Inc., the second entrant, claiming the company infringed a patent on a method of making enoxaparin.
On July 21, a Massachusetts jury issued a verdict that although Amphastar infringed the patent, No. 7,575,886, it was invalid and unenforceable
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?